Evaluation Challenges in the validation of B7-H3 as oral tongue cancer prognosticator by Sieviläinen, Meri et al.
Vol.:(0123456789) 
Head and Neck Pathology 
https://doi.org/10.1007/s12105-020-01222-3
ORIGINAL PAPER
Evaluation Challenges in the Validation of B7-H3 as Oral Tongue 
Cancer Prognosticator
Meri Sieviläinen1,2 · Anna Maria Wirsing3 · Aini Hyytiäinen1,2 · Rabeia Almahmoudi1,2 · Priscila Rodrigues4,5 · 
Inger‑Heidi Bjerkli3,6 · Pirjo Åström4,5 · Sanna Toppila‑Salmi7 · Timo Paavonen8 · Ricardo D. Coletta9 · 
Elin Hadler‑Olsen3,10 · Tuula Salo1,2,4,5,11 · Ahmed Al‑Samadi1,2 
Received: 19 July 2020 / Revised: 31 August 2020 / Accepted: 3 September 2020 
© The Author(s) 2020
Abstract
B7-H3 was the only molecule identified with prognostic potential from a recent systematic review of the prognostic value 
of immune checkpoints in oral cancer. We aimed to validate this finding in a multicenter international cohort. We retrospec-
tively retrieved 323 oral tongue squamous cell carcinoma (OTSCC) samples from three different countries (Brazil, Finland, 
and Norway) for immunostaining and scoring for B7-H3. We evaluated tumor immunogenicity by analyzing the amount of 
tumor-infiltrating lymphocytes and divided the tumors into immune hot and cold. To increase the reliability of the results, 
both digital and manual visual scoring were used. Survival curves were constructed based on the Kaplan-Meier method, and 
the Cox proportional hazard model was utilized for univariate and multivariate survival analysis. B7-H3 expression was not 
significantly associated with overall or disease-specific survival in the whole OTSCC cohort. When divided into immune hot 
and cold tumors, high B7-H3 expression was significantly associated with poor disease-specific and overall survival in the 
immune hot group, depending on the scoring method and the country of the cohort. This was achieved only in the univariate 
analysis. In conclusion, B7-H3 was a negative prognosticator for OTSCC patient survival in the subgroup of immune hot 
tumors, and was not validated as a prognosticator in the full cohort. Our findings suggest that the immune activity of the 
tumor should be considered when testing immune checkpoints as biomarkers.
Keywords Oral tongue squamous cell carcinoma · B7-H3 · Tumor infiltrating lymphocytes · Immune checkpoint · 
Replication crisis.
Introduction
The incidence of oral together with lip squamous cell car-
cinoma (OSCC) is unfortunately increasing. In 2018, the 
number of new cases worldwide was approximately 350,000 
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with an annual mortality of approximately 180,000 [1]. This 
increase is not associated with an increase in the 5-year sur-
vival rate, which remains at approximately 50% for most 
countries [1, 2]. Therefore, there is a need for new treatment 
and therapeutic approaches. OSCC arising from the tongue 
(OTSCC) is the most aggressive subgroup of oral cancers 
and is characterized by high rates of metastasis and mortality 
[3]. OTSCC carcinogenesis is traditionally associated with 
heavy alcohol and tobacco use [4]. In addition, evasion of 
the host immune response to the tumor has been recognized 
as a key feature in the carcinogenesis process, and tumors 
with low infiltration of immune cells respond more poorly to 
immune-based cancer therapies [5]. These findings have led 
the way to a novel classification of tumors into two catego-
ries, “hot” (or inflamed) and “cold” (or non-inflamed), based 
on quantification of tumor-infiltrating lymphocytes (TILs) 
[6]. Head and neck cancers are generally highly infiltrated 
by lymphocytes and are thus immune hot; however, the 
poor patient survival suggests that the anti-tumor immune 
response is ineffective [7].
Immune checkpoints play a predominant role in the initia-
tion of  CD4+ and  CD8+ T cell-dependent immune responses 
by regulating interactions between co-stimulatory ligands 
and their receptors [8]. Ligand members of the B7/CD28 
superfamily, such as B7-H1 (PD-L1) and B7-H3, can modu-
late the initiation by either amplifying or inhibiting co-stim-
ulatory signals. PD-L1 overexpression inhibits the activation 
of functional T-cells [9] and PD-1/PD-L1 axis inhibition 
has been adopted as a therapeutic approach for OSCC [10]. 
On the other hand, B7-H3 has no identified receptors and 
is theorized to be involved in both co-stimulation and co-
inhibition of T cells [11]. In vitro, B7-H3 increases activity 
of CD8 + T cells but also inhibits T-cell proliferation and 
reduces secretion of relevant immune mediators such as 
interferon-γ, tumor necrosis factor α, and other cytokines 
[12, 13].
Several studies have been conducted to determine the 
prognostic value of immune checkpoints in oral cancer [14]. 
In our recent systematic review, B7-H3 showed evidence as 
an adverse prognostic factor in OSCC, while other immune 
checkpoints were either studied once or had controversial 
results [14]. According to Almangush and co-authors, hun-
dreds of biomarkers have been studied as prognostic markers 
for OSCC, but none are in clinical use [15]. This may be due 
to several factors, mainly missing validation, as among the 
12 immune-modulating molecules investigated thus far, only 
four had been studied more than once.
Since B7-H3 was the only immune checkpoint molecule 
that showed a potential role in the prognostication of OSCC, 
we sought to validate this result in a multicenter interna-
tional cohort study.
Methods and Materials
This study was performed according to the REMARK guide-
lines for tumor marker prognostic studies [16].
Patient Samples
This study examined a total of 323 retrospective OTSCC 
samples obtained during tumor surgery from three different 
countries: 147 formalin-fixed paraffin-embedded (FFPE) 
whole-section samples from Finland (Oulu and Tampere 
University hospitals, collected during 1990–2010), 132 
FFPE tumor microarray (TMA) samples from Norway 
(the University hospitals of Oslo, Bergen, Trondheim and 
Tromsø, collected during 2005–2009), and 44 FFPE whole-
section samples from Brazil (UOPECCAN and CEONC 
Cancer Hospitals in Cascavel-Parana, collected during 
2008–2014). Patients received treatment according to the 
respective national guidelines. In Finland, the data inquiry 
was approved by the National Supervisory Authority for 
Welfare and Health (VALVIRA) and the Ethics Committee 
of the Northern Ostrobothnia Hospital District (statement 
#8/2006, amendment 19/10/2006). The OTSCC sample col-
lection in Brazil was approved by the Human Research Eth-
ics Committee of the Piracicaba Dental School, University 
of Campinas. In Norway, the study was approved by the 
Institutional Review Board of Northern Norwegian Regional 
Committee for Medical Research Ethics (REK Nord) with 
validated approval for all hospitals (Protocol number REK 
Nord; 2013/1786 and 2015/1381). The clinical and demo-
graphic parameters of the patients are presented in Table 1.
Immunohistochemical Staining
For optimizing the staining protocol, we used the follow-
ing two antibodies for B7-H3: rabbit anti-human B7-H3 
(D9M2L, 1:200, Cell Signaling technology, Leiden, Nether-
lands) and goat anti-human B7-H3 (AF1027, 1:1000, R&D-
systems, Minneapolis, MN, USA). Antibody selection was 
based on two published articles [8, 17]. Three researchers 
(M.S. junior trainee; A.A-S., senior trainee; and T.S., oral 
pathologist) evaluated the staining with an optical micro-
scope (Leica DM6000 together with Leica DFC365-FX 
camera, Leica Biosystems, Newcastle, UK). Both antibod-
ies had the same staining pattern with slight differences in 
staining intensity (Online Resource 1); therefore both were 
used in this study. The Finnish samples were stained with 
rabbit anti-human antibody and the Norwegian and Brazilian 
samples were stained with goat anti-human antibody.
For the rabbit antibody, Dako Real EnVision Detection 
system K5007 kit (Dako, Carpinteria, CA) was used for 
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staining. After deparaffinization, epitopes were retrieved in 
Tris-EDTA buffer (pH 9) for 15 minutes using a microwave 
and followed by cooling at room temperature for 20 minutes. 
Dako Peroxidase blocking solution S2023 was next applied 
for 15 minutes. Sections were then incubated with the rab-
bit B7-H3 primary antibody for 1 hour at room temperature 
followed by Dako HRP for 30 minutes at room temperature.
For the goat-based antibody, we used a goat on rodent 
HRP-polymer detection kit (Biocare Medical, Pacheco, CA). 
After deparaffinization, antigens were retrieved in citrate 
buffer (Dako) for 15 minutes using a microwave and fol-
lowed by cooling at room temperature for 20 minutes. Dako 
peroxidase blocking solution S2023 was then applied for 15 
minutes. Sections were then incubated with the goat B7-H3 
primary antibody for 30 minutes. Goat probe from the detec-
tion kit was added for 15 minutes and followed by goat on 
rodent HRP polymer for 15 minutes.
Both rabbit and goat sections were then incubated with 
chromogen DAB for color formation for 15 minutes and 
washed in  dH2O for 5 minutes. The slides were then counter-
stained with Mayer’s hematoxylin solution (Sigma-Aldrich, 
St. Louis, MO, USA) and mounted in Mountex (HistoLab, 
Gothenburg, Sweden).
Slides were scanned using a Leica Aperio AT2 (Leica 
Biosystems) to be analyzed using QuPath software.18 The 
specificity of each staining was confirmed with staining 
controls.
Assessment of B7‑H3 Expression using Manual 
Visual Scoring
Two researchers for each cohort (Finland: A.H., junior 
trainee, M.S. junior trainee; Norway: A.W., senior trainee, E. 
H-O., senior trainee; Brazil: P.C., senior trainee, P.Å., senior 
Table 1  Demographic and 
clinicopathological parameters 
of the oral tongue squamous cell 
carcinoma patients
*Norwegian cases have 11 samples with some missing clinical data
Patient clinical data No. of patients 
(%) n = 323
Brazil    n = 44 Finland   n = 147 Norway n = 132
Age
 < 60 135 (40.8) 29 (65.9) 63 (42.9) 43 (32.6)
 ≥ 60 188 (56.8) 15 (34.1) 84 (57.1) 89 (67.4)
Range 17–99 31–83 17–99 25–90
Mean 62.60 48.4 63.1 64.3
Median 63 49 65 65
Sex
 Male 192 (58.0) 37 (84.1) 76 (51.7) 79 (59.8)
 Female 131 (39.6) 7 (15.9) 71 (48.3) 53 (40.2)
Tumor grade
 I-II, Mild to moderate 265 (82.0) 38 (86.4) 114 (77.6) 113 (85.6)
 III, Poor 52 (16.1) 6 (13.6) 33 (22.4) 13 (9.8)
 Missing* 6 (1.9) 0 (0) 0 (0) 6 (4.5)
Tumor stage
 T1-T2 233 (72.1) 37 (84.1) 89 (60.5) 102 (77.3)
 T3-T4 79 (24.5) 7 (15.9) 58 (39.5) 10 (7.6)
 Missing* 11 (3.4) 0 (0) 0 (0) 11 (8.3)
Neck metastasis
 N1 108 (33.4) 19 (43.2) 74 (50.3) 28 (21.2)
 N0 204 (63.2) 25 (56.8) 72 (49.0) 93 (70.5)
 Missing* 11 (3.4) 0 (0) 0 (0) 11 (8.3)
Treatment
 Surgery 116 (35.9) 13 (29.5) 73 (49.7) 30 (22.7)
 Surgery and radiotherapy 131 (40.6) 15 (34.1) 22 (15.0) 94 (71.2)
 Surgery,
radio- and chemotherapy
76 (23.5) 16 (36.4) 52 (35.3) 8 (6.1)
Recurrence
 No recurrence 224 (69.3) 33 (75.0) 88 (60.0) 103 (78.0)
 Recurrence 91 (28.2) 11 (25.0) 58 (39.5) 21 (15.9)
 Missing* 8 (2.5) 0 (0) 0 (0) 8 (2.5)
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trainee) evaluated all scanned samples independently and 
then jointly for consensus while blinded to any clinical data.
Staining intensity was evaluated as 0–3 (0: negative, 1: 
weak, 2: moderate, and 3: strong; Fig. 1) and the staining 
area was evaluated as 0–3 (0: 0%, 1: 0 > 25%, 2: 25 > 50%, 
3: >50%). The staining index was calculated as a sum of the 
two scores. The Norwegian TMA samples did not allow a 
meaningful evaluation of the staining area, thus only staining 
intensity is reported from these samples.
Assessment of B7‑H3 Expression using Digital 
Scoring
In addition to the traditional manual visual scoring, we 
sought to validate our results by using a free, automated 
analysis software, QuPath [18]. Two researchers (M.S. 
and P.C.) with coding experience developed the automated 
scoring protocol. First, the program was calibrated to detect 
colors by estimating the staining vectors. All FFPE and 
TMA samples had similar modal RGB and DAB values. 
Fig. 1  B7-H3 expression in 
oral tongue squamous cell 
carcinoma cells: a-b. Negative 
staining (intensity = 0), c-d. 
Mild staining (intensity = 1), 
e-f. Moderate staining (inten-
sity = 2), g-h. Strong staining 
(intensity = 3). Scale bar a, c, e, 
g, 100 µm; b, d, f, h, 50 µm
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Second, the classifier was taught to recognize cancer and 
stromal cells by choosing five areas of tumor and five areas 
of stroma for ten slides. Cell and membrane detection was 
performed according to the developer instructions (Online 
Resource 2). Third, the classifier was calibrated by compar-
ing different mean DAB OD values for different slides from 
different countries to determine the thresholds to be used. 
Both researchers performed the analysis first independently 
and then agreed on the values to be used on all slides (Online 
Resource 2). The classifier was then saved and the script 
was coded. One researcher (Finland: M.S.; Brazil: P.C.) for 
each cohort selected 5 representative areas of the invasive 
front in FFPE samples, TMA was taken as a whole, and ran 
the automated software. The scripts are available in Online 
Resource 3 and 4. Results were in the form of H-score and 
were extracted for survival analysis.
Tumor‑Infiltrating Lymphocytes (TILs) Scoring
Two researchers (A.H.; junior trainee, M.S.; junior trainee) 
evaluated the presence of TILs in the Brazilian and Finnish 
samples independently and divided the cases into immune 
hot and cold while remaining blinded to any clinical data 
[6]. Disagreements between evaluators were resolved by an 
experienced researcher (A.A-S; senior trainee). Scoring was 
conducted as previously described [19]. Based on this study, 
only stromal TILs were assessed. The scoring was defined 
as the percentage of stroma occupied by lymphocytes (0%, 
5%, 10%, 20%, 30%, 40%, and ≥ 50%). Only areas directly 
related to the invasive front were included in the estima-
tion. Areas of fibrosis, central necrosis, or artefacts were 
excluded. Norwegian cases were not scored for the TILs as 
they were TMAs, which do not allow the full evaluation of 
the tumor stroma.
Inter‑Rater Reliability
A κ coefficient was calculated to measure the agreement 
between evaluators. Interpretation of the κ coefficient was 
based on Landis and Koch 1977 (poor agreement: less 
than 0.20, fair agreement: 0.20–0.40, moderate agreement: 
0.40–0.60, substantial agreement: 0.60–0.79, and almost 
perfect agreement: 0.80–1.00) [20]. The highest agreement 
in the manual visual scoring of B7-H3 between the evalu-
ators was in the Norwegian (κ-value 0.84, 95% confidence 
interval 0.81–0.89) and Brazilian (κ -value 0.83, 95% con-
fidence interval 0.70–0.97) cases, reaching almost perfect 
agreement followed by Finnish cases (κ -value 0.57, 95% 
confidence interval 0.51–0.64) with moderate agreement. 
For TIL scoring, there was moderate agreement between 
the evaluators (κ-value 0.55, 95% confidence interval 
0.51–0.59).
Statistical Analysis
After scoring, cases were divided into high and low expres-
sion using the median as the cut-off point. We also per-
formed the analysis by calculating the optimal cut-off point 
[21], but this did not change the results (data not shown). 
Additionally, the cases were divided into immune hot if TILs 
were ≥ 20%, and cold if median TILs were < 20%, based on 
a previous study [19]. The κ coefficient was calculated and 
Fig. 2  B7-H3 location and 
expression pattern. B7-H3 is 
mainly located at the cancer cell 
membrane (a) and sometimes 
was observed in the cancer cell 
cytoplasm (b). In most of the 
slides, B7-H3 was expressed 
only at the periphery of the 
tumor island (c) and in some 
cases was expressed in the 
whole tumor island (d). Scale 
bar a, b 50 μm; b, d 250 μm
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the prognosis of patients in relation to overall survival and 
disease-specific mortality was analyzed using SPSS software 
program version 21.0 (IBM SPSS Statistics, SPSS INC, Chi-
cago, IL, USA). Life tables were calculated according to 
the Kaplan-Meier method. Survival curves were compared 
with the log-rank test. Univariate and multivariate survival 
analyses were performed with Cox’s proportional hazards 
model. In multivariate analysis, the results were adjusted for 
age, sex, grade, stage, and lymph node metastasis. Statistical 
significance was set at p < 0.05.
Results
B7‑H3 Expression in OTSCC Samples
B7-H3 was mainly expressed at the membrane of the cancer 
cells (Fig. 2a). Staining was also seen in the cytoplasm in 
some heavily stained samples, (Fig. 2b). The staining was 
mainly concentrated at the periphery of the tumor islands 
(Fig. 2c). However, the whole tumor island was positive in 
some cases (Fig. 2d).
B7‑H3 Expression is not Associated with Survival 
of OTSCC Patients
During follow-up, 120 patients died of OTSCC, 56 patients 
died of other causes, and 147 patients were alive at the end 
of the follow-up period. Median follow-up time was 40 
months (range: 0–252 months). B7-H3 expression was not 
significantly associated with OTSCC mortality (Table 2). 
We performed the analysis for each country separately to 
determine if differences in population or laboratories had 
any impact on the results. All subgroups showed similar 
results to the combined data, which indicated that B7-H3 is 
not significantly associated with disease-specific or overall 
survival (Table 2). Even with the optimal cut-off points, no 
significance was found in any of the subgroups (data not 
shown).
Table 2  Univariate survival analysis for disease specific and overall survival based on B7-H3 expression. Low B7-H3 is taken as a reference
All samples (n = 323)
Disease specific survival Overall survival
HR (95%CI) p-value HR (95%CI) p-value
Digital scoring 0.91 (0.63–1.30) 0.58 1.00 (0.75–1.35) 0.98
Manual visual scoring intensity 0.97 (0.67–1.40) 0.88 1.07 (0.79–1.45) 0.64
Brazil (n = 44)
Disease specific survival Overall survival
HR (95%CI) p-value HR (95%CI) p-value
Digital scoring 1.29 (0.56–2.94) 0.55 1.91 (0,89-4.11) 0.10
Manual visual scoring index 1.02 (0.45–2.33) 0.97 1.17 (0.56–2.48) 0.68
Manual visual scoring intensity 0.97 (0.43–2.21) 0.94 1.24 (0.59–2.62) 0.57
Manual visual scoring area 1.13 (0.49–2.57) 0.77 1.21 (0.57–2.56) 0.61
Finland (n = 147)
Disease specific survival Overall survival
HR (95%CI) p-value HR (95%CI) p-value
Digital scoring 1.19 (0.67–2.12) 0.55 1.05 (0.67–1.65) 0.82
Manual visual scoring index 1.4 (0.78–2.5) 0.25 1.32 (0.84–2.09) 0.22
Manual visual scoring intensity 0.75 (0.42–1.34) 0.33 0.74 (0.47–1.17) 0.20
Manual visual scoring area 1.72 (0.97–3.39) 0.10 1.54 (0.91–2.58) 0.10
Norway (n = 132)
Disease specific survival Overall survival
HR (95%CI) p-value HR (95%CI) p-value
Digital scoring 1.16 (0.67–2.03) 0.60 1.26 (0.79–2.01) 0.33
Manual visual scoring intensity 0.91 (0.52–1.59) 0.75 1.01 (0.63–1.6) 0.97
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Fig. 3  Survival curves of the B7-H3 high and low expression for 
immune hot cases. Kaplan-Meier curves representing the Finnish 
cases for disease-specific survival (a) and overall survival (b), Brazil-
ian cases for disease-specific survival (c) and overall survival (d) and 
all cases (Finnish and Brazilian) for disease-specific survival (e) and 
overall survival (f)
 Head and Neck Pathology
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High B7‑H3 Expression is Associated with Poor 
Survival in the Immune Hot Subgroup of OTSCC 
Patients
As B7-H3 mainly exerts its effects on lymphocytes, we 
divided the cancer samples into immune hot or cold (high 
or low amount of TILs, respectively) and performed the 
analysis for each group separately. The TMA samples from 
Norway could not be separated into these two groups. In 
immune hot cases, high B7-H3 expression associated with 
low overall survival in digitally scored Brazilian samples, 
and with low disease-specific survival in manually visu-
ally scored (scoring index and area) Finnish cases (Table 3; 
Fig. 3). The significant association was not observed in mul-
tivariate analysis (data not shown). In immune cold cases, no 
significant correlation was found between B7-H3 expression 
and patient survival in any of these analyses (Table 3).
Discussion
This multicenter international study sought to validate the 
prognostic value of B7-H3 in OTSCC, as this immune 
checkpoint was reported as a prognostic marker twice in 
head and neck and OSCC [8, 17]. In our OTSCC patient 
cohort, high B7-H3 expression was associated with poorer 
prognosis in some national subgroups but only for those 
whose tumors were highly infiltrated by lymphocytes 
(immune hot); depending on the scoring method, but it failed 
to work in the full cohort. A significant association was only 
found in the univariate but not the multivariate analysis.
Our results highlight a common and serious problem in 
prognostic marker studies, which can be called the “rep-
lication crisis” [22]. Recent systematic reviews of prog-
nostic markers for oral cancer have suggested hundreds of 
molecules as putative prognostic markers [14, 15, 23, 24]. 
Table 3  Univariate survival analysis results for B7-H3 expression in immune hot and cold samples. Low B7-H3 is taken as a reference
Brazil + Finland 
(n = 191)
Immune hot cases (n = 116) Immune cold cases (n = 75)
Disease specific survival Overall survival Disease specific survival Overall survival
HR (95%CI) p-value HR (95%CI) p-value HR (95%CI) p-value HR (95%CI) p-value
Digital Scoring 1.05 (0.56–1.97) 0.87 1.01 (0.59–1.72) 0.96 0.77 (0.38–1.57) 0.47 0.72 (0.41–1.26) 0.25
Manual Visual 
Scoring Index
1.85 (0.97–3.53) 0.06 1.47 (0.87–2.49) 0.15 0.66 (0.32–1.35) 0.25 0.89 (0.51–1.57) 0.69
Manual Visual 
Scoring Intensity
0.71 (0.38–1.33) 0.29 0.71 (0.41–1.19) 0.19 0.77 (0.37–1.58) 0.47 0.89 (0.49–1.61) 0.71
Manual Visual 
Scoring Area
1.78 (0.90–3.51) 0.09 1.42 (0.82–2.46) 0.21 0.74 (0.32–1.58) 0.44 0.92 (0.47–1.79) 0.81
Brazil (n = 44) Immune hot cases (n = 27) Immune cold cases (n = 17)
Disease specific survival Overall survival Disease specific survival Overall survival
HR (95%CI) p-value HR (95%CI) p-value HR (95%CI) p-value HR (95%CI) p-value
Digital Scoring 3.14 (0.92–10.66) 0.06 4.24 (1.30-13.82) 0.01 0.40 (0.10–1.58) 0.17 0.48 (0.14–1.6) 0.21
Manual Visual 
Scoring Index
0.84 (0.28–2.52) 0.76 0.85 (0.31–2.36) 0.76 0.68 (0.14–3.24) 0.62 1.03 (0.30–3.48) 0.96
Manual Visual 
Scoring Intensity
1.44 (0.48–4.33) 0.50 1.523 (0.54–4.22) 0.41 0.57 (0.07–4.59) 0.59 1.43 (0.38–5.30) 0.58
Manual Visual 
Scoring Area
1.37 (0.43–4.35) 0.58 1.08 (0.36–3.23) 0.88 0.68 (0.14–3.24) 0.62 1.03 (0.30–3.48) 0.96
Finland (n = 147) Immune hot cases (n = 89) Immune cold cases (n = 58)
Disease specific survival Overall survival Disease specific survival Overall survival
HR (95%CI) p-value HR (95%CI) p-value HR (95%CI) p-value HR (95%CI) p-value















3.30 (1.14–9.57) 0.02 1.85 (0.90–3.79) 0.08 0.79 (0.32–1.99) 0.62 0.93 (0.43–
2.03)
0.86
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However, none of them have been adopted into clinical use, 
and patient management is still mainly based on the clinical 
TNM staging due to missing or failed validation [15].
In the two previous studies on B7-H3 [8, 17], both patient 
cohorts were from Asia (Taiwan and Wuhan). National sub-
groups tend to have exposure differences to risk factors for 
OSCC, such as heavy tobacco, alcohol, and betel nut use. 
This explains why results from OSCC cohorts from one part 
of the world are not necessarily applicable to others. In addi-
tion, the samples analyzed in the two previous articles were 
obtained from the whole oral cavity and the head and neck 
area while our samples were only from the tongue [8, 17]. 
In contrast to OTSCC, HPV infection is recognized as an 
important risk factor for oropharyngeal cancers, underlin-
ing the need to distinguish these cancers [25]. Differences 
in ethnicity and tumor location could be the reason why we 
failed to validate B7-H3 in our patient cohort. In this study, 
we collected samples from three different nations (Brazil, 
Finland, and Norway) representing OTSCC patients of dif-
ferent ethnicities. This resulted in a large sample size com-
bating statistical bias.
To analyze the quality and repeatability of our scoring, 
we measured inter-rater reliability for manual visual scoring 
with a κ coefficient. The highest scores and almost perfect 
agreement were achieved by senior trainees. Junior trainees 
had the lowest score with moderate agreement. Thus, extra 
care should be taken when selecting those who score the 
stained slides and we recommend that the slides evaluation 
is done by pathologists who have enough expertise in this 
field.
The field of pathology is rapidly moving towards auto-
mated digital scoring and the use of artificial intelligence 
[26]. In addition to manual visual scoring, we scored the 
slides using the free automated software QuPath. Use of 
automated software not only reduces the time for scoring 
but also increases the reliability of the results and reduces 
the risk of bias [26]. One of the major challenges of apply-
ing this software as a scoring tool is the difference in set-
tings between laboratories and investigators. Thus, we highly 
recommend that authors publish all adjustable settings to 
allow others to replicate and validate the work. Even though 
the digital and manual visual scoring went hand-by hand in 
the majority of cases, still in some cases they gave differ-
ent results which call for a better digital and manual visual 
scoring protocols.
Another serious problem in the field of prognostic marker 
studies and validation is related to variation of antibody 
specificity. Theoretically, all antibodies should give simi-
lar results if the antibody passes the manufacturer’s qual-
ity control. Unfortunately, in practice there are large vari-
ations, not just between different antibodies from different 
manufacturers, but also between different lots from the same 
manufacturer. For this reason, we tested two antibodies from 
two different companies, which, fortunately, gave similar 
staining patterns.
Immune checkpoints, including B7-H3, are group of 
molecules with effects on immune cells. Recent advance-
ments in cancer immune therapeutics have resulted in 
tumors being categorized into hot and cold.6 Therefore, 
in this study we investigated lymphocyte infiltration in 
the invasive area of the tumor tissue. While our survival 
results were insignificant in the entire cohort, we observed 
significant results in hot tumors in the univariate analysis. 
Our findings further indicate that without the affected cells 
(lymphocytes) in the tumor, the prognostic power of B7-H3 
(and likely also other immune checkpoint inhibitors) may 
be lost. Thus, we stress the necessity of investigating the 
immune activity of tumors when assessing the prognostic 
value of B7-H3 expression.
As a conclusion, in this multicenter international study, 
evaluation of B7-H3 expression revealed prognostic poten-
tial for patients with tumors that were highly infiltrated 
with lymphocytes. However, B7-H3 did not have prog-
nostic value in the whole OTSCC cohort. This study high-
lighted an important issue in the field of prognostic markers, 
which is the “replication crisis”. For prognostic studies on 
immune checkpoints, we encourage researchers to analyze 
the immune activity of the tumor samples. We also encour-
age researchers to publish the scoring protocols (either by 
manual visual or digital scoring) in detail with all adjustable 
parameters to allow careful replication and validation of the 
work. Only immunohistochemical markers with prognostic 
power validated in several research groups and from cohorts 
of different countries may have the potential to become a 
useful tool for universal clinical pathology.
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